A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VSF-173 and Matching Placebo in Healthy Male and Female Subjects With Induced Excessive Sleepiness

Further study details as provided by Vanda Pharmaceuticals:

Primary Outcome Measures:

Ability to stay awake as assessed by Maintenance of Wakefulness Test (MWT)

Secondary Outcome Measures:

Mood

Psychomotor performance

Safety and tolerability

Estimated Enrollment:

60

Eligibility

Ages Eligible for Study:

18 Years to 40 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Healthy subjects with no medical, psychiatric, or current sleep disorders

Subject must sign a written consent form

Exclusion Criteria:

Evidence of excessive daytime sleepiness

History of sleep disorders

Psychiatric or neurological disorders

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00467441